_version_ 1785033039467773952
author Bezerra, Evandro D.
Iqbal, Madiha
Munoz, Javier
Khurana, Arushi
Wang, Yucai
Maurer, Matthew J.
Bansal, Radhika
Hathcock, Matthew A.
Bennani, Nora
Murthy, Hemant S.
Rosenthal, Allison C.
Paludo, Jonas
Villasboas, Jose C.
Johnston, Patrick B.
Habermann, Thomas M.
Ansell, Stephen M.
Castro, Januario E.
Witzig, Thomas E.
Kharfan-Dabaja, Mohamed A.
Nowakowski, Grzegorz S.
Lin, Yi
author_facet Bezerra, Evandro D.
Iqbal, Madiha
Munoz, Javier
Khurana, Arushi
Wang, Yucai
Maurer, Matthew J.
Bansal, Radhika
Hathcock, Matthew A.
Bennani, Nora
Murthy, Hemant S.
Rosenthal, Allison C.
Paludo, Jonas
Villasboas, Jose C.
Johnston, Patrick B.
Habermann, Thomas M.
Ansell, Stephen M.
Castro, Januario E.
Witzig, Thomas E.
Kharfan-Dabaja, Mohamed A.
Nowakowski, Grzegorz S.
Lin, Yi
author_sort Bezerra, Evandro D.
collection PubMed
description
format Online
Article
Text
id pubmed-10139860
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The American Society of Hematology
record_format MEDLINE/PubMed
spelling pubmed-101398602023-04-29 Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy Bezerra, Evandro D. Iqbal, Madiha Munoz, Javier Khurana, Arushi Wang, Yucai Maurer, Matthew J. Bansal, Radhika Hathcock, Matthew A. Bennani, Nora Murthy, Hemant S. Rosenthal, Allison C. Paludo, Jonas Villasboas, Jose C. Johnston, Patrick B. Habermann, Thomas M. Ansell, Stephen M. Castro, Januario E. Witzig, Thomas E. Kharfan-Dabaja, Mohamed A. Nowakowski, Grzegorz S. Lin, Yi Blood Adv Research Letter The American Society of Hematology 2022-10-14 /pmc/articles/PMC10139860/ /pubmed/36219588 http://dx.doi.org/10.1182/bloodadvances.2022007868 Text en © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Letter
Bezerra, Evandro D.
Iqbal, Madiha
Munoz, Javier
Khurana, Arushi
Wang, Yucai
Maurer, Matthew J.
Bansal, Radhika
Hathcock, Matthew A.
Bennani, Nora
Murthy, Hemant S.
Rosenthal, Allison C.
Paludo, Jonas
Villasboas, Jose C.
Johnston, Patrick B.
Habermann, Thomas M.
Ansell, Stephen M.
Castro, Januario E.
Witzig, Thomas E.
Kharfan-Dabaja, Mohamed A.
Nowakowski, Grzegorz S.
Lin, Yi
Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy
title Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy
title_full Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy
title_fullStr Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy
title_full_unstemmed Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy
title_short Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy
title_sort barriers to enrollment in clinical trials of patients with aggressive b-cell nhl that progressed after car t-cell therapy
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139860/
https://www.ncbi.nlm.nih.gov/pubmed/36219588
http://dx.doi.org/10.1182/bloodadvances.2022007868
work_keys_str_mv AT bezerraevandrod barrierstoenrollmentinclinicaltrialsofpatientswithaggressivebcellnhlthatprogressedaftercartcelltherapy
AT iqbalmadiha barrierstoenrollmentinclinicaltrialsofpatientswithaggressivebcellnhlthatprogressedaftercartcelltherapy
AT munozjavier barrierstoenrollmentinclinicaltrialsofpatientswithaggressivebcellnhlthatprogressedaftercartcelltherapy
AT khuranaarushi barrierstoenrollmentinclinicaltrialsofpatientswithaggressivebcellnhlthatprogressedaftercartcelltherapy
AT wangyucai barrierstoenrollmentinclinicaltrialsofpatientswithaggressivebcellnhlthatprogressedaftercartcelltherapy
AT maurermatthewj barrierstoenrollmentinclinicaltrialsofpatientswithaggressivebcellnhlthatprogressedaftercartcelltherapy
AT bansalradhika barrierstoenrollmentinclinicaltrialsofpatientswithaggressivebcellnhlthatprogressedaftercartcelltherapy
AT hathcockmatthewa barrierstoenrollmentinclinicaltrialsofpatientswithaggressivebcellnhlthatprogressedaftercartcelltherapy
AT bennaninora barrierstoenrollmentinclinicaltrialsofpatientswithaggressivebcellnhlthatprogressedaftercartcelltherapy
AT murthyhemants barrierstoenrollmentinclinicaltrialsofpatientswithaggressivebcellnhlthatprogressedaftercartcelltherapy
AT rosenthalallisonc barrierstoenrollmentinclinicaltrialsofpatientswithaggressivebcellnhlthatprogressedaftercartcelltherapy
AT paludojonas barrierstoenrollmentinclinicaltrialsofpatientswithaggressivebcellnhlthatprogressedaftercartcelltherapy
AT villasboasjosec barrierstoenrollmentinclinicaltrialsofpatientswithaggressivebcellnhlthatprogressedaftercartcelltherapy
AT johnstonpatrickb barrierstoenrollmentinclinicaltrialsofpatientswithaggressivebcellnhlthatprogressedaftercartcelltherapy
AT habermannthomasm barrierstoenrollmentinclinicaltrialsofpatientswithaggressivebcellnhlthatprogressedaftercartcelltherapy
AT ansellstephenm barrierstoenrollmentinclinicaltrialsofpatientswithaggressivebcellnhlthatprogressedaftercartcelltherapy
AT castrojanuarioe barrierstoenrollmentinclinicaltrialsofpatientswithaggressivebcellnhlthatprogressedaftercartcelltherapy
AT witzigthomase barrierstoenrollmentinclinicaltrialsofpatientswithaggressivebcellnhlthatprogressedaftercartcelltherapy
AT kharfandabajamohameda barrierstoenrollmentinclinicaltrialsofpatientswithaggressivebcellnhlthatprogressedaftercartcelltherapy
AT nowakowskigrzegorzs barrierstoenrollmentinclinicaltrialsofpatientswithaggressivebcellnhlthatprogressedaftercartcelltherapy
AT linyi barrierstoenrollmentinclinicaltrialsofpatientswithaggressivebcellnhlthatprogressedaftercartcelltherapy